Signs & PortentsWe'll know we're getting closer to acceptance by the medical community when the uro oncologist coauthors with
Dr. Kulkarni of the ASCO presentation begin to make (unforced) encouraging comments about TLD1433 pdt as an exciting upcoming option for BCG unresponsive NMIBC.
These fellows - the ones who are running the trial:
Dr. Kyle Richards, University of Wisconsin Madison
Dr. Peter Black, University of British Columbia
Dr. Ricardo Rendon, Dalhousie University
Dr. Joseph Chin, London Health Sciences Centre
Dr. Neal Shore, Carolina Urologic Research Center
Dr. Gautam Jayram, Urology Associates, Nashville, TN
Dr. Eugene V. Kramolowsky, Virginia Urology Center
Dr. Daniel Saltzstein, Urology San Antonio
Dr. Piyush K. Agarwal, University of Chicago Medical Center
Dr. Laurence Belkoff, Midlantic Urology
Dr. Donald L. Lamm, BCG Oncology, Phoenix, AZ
Dr. Victor DeGruttola, Harvard University
Dr. Wassim Kassouf, McGill University Health Centre
also, our Medical and Scientific Advisory Board:
Dr. Ashish M. Kamat, MD Anderson
Dr. Michael A. O’Donnell, University of Iowa
Plus former longtime MSAB member (2013-2022) and TLD1433 phase 2 clinical study designer
Dr. Michael A.S. Jewett, Princess Margaret - UHN